Gilead Sciences, Inc. $GILD Stock Acquired by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,972,668 shares of the biopharmaceutical company’s stock after acquiring an additional 10,020 shares during the period. Sumitomo Mitsui Trust Group Inc. owned approximately 0.24% of Gilead Sciences worth $443,076,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Client 1ST Advisory Group LLC lifted its position in shares of Gilead Sciences by 4.0% in the 3rd quarter. Client 1ST Advisory Group LLC now owns 1,786 shares of the biopharmaceutical company’s stock valued at $266,000 after acquiring an additional 69 shares in the last quarter. Grove Bank & Trust grew its holdings in shares of Gilead Sciences by 1.2% during the third quarter. Grove Bank & Trust now owns 6,345 shares of the biopharmaceutical company’s stock valued at $946,000 after buying an additional 74 shares in the last quarter. Financial Connections Group Inc. grew its stake in Gilead Sciences by 30.2% during the 1st quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 76 shares in the last quarter. Wilkerson Advisory Group LLC increased its stake in Gilead Sciences by 54.2% in the 1st quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 78 shares during the period. Finally, HBW Advisory Services LLC increased its stake in shares of Gilead Sciences by 2.4% in the first quarter. HBW Advisory Services LLC now owns 3,391 shares of the biopharmaceutical company’s stock worth $473,000 after acquiring an additional 79 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

GILD has been the subject of a number of analyst reports. Needham & Company LLC set a $175.00 price target on Gilead Sciences in a research report on Friday. Royal Bank Of Canada raised their price target on Gilead Sciences from $126.00 to $131.00 and gave the company a “sector perform” rating in a research report on Friday. Wells Fargo & Company lifted their price objective on Gilead Sciences from $165.00 to $190.00 and gave the stock an “overweight” rating in a research note on Friday. Barclays cut their price objective on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 29th. Finally, Cantor Fitzgerald increased their target price on Gilead Sciences from $155.00 to $175.00 and gave the company an “overweight” rating in a research note on Friday. Twenty-three investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $169.19.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel O’Day sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $148.64, for a total transaction of $2,229,600.00. Following the transaction, the chief executive officer owned 577,133 shares of the company’s stock, valued at $85,785,049.12. The trade was a 2.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Dickinson sold 3,000 shares of the stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total value of $468,660.00. Following the completion of the sale, the chief financial officer owned 161,096 shares in the company, valued at approximately $25,166,417.12. This trade represents a 1.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 111,000 shares of company stock worth $15,877,860 over the last ninety days. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD stock opened at $170.68 on Friday. The firm has a fifty day moving average of $150.87 and a 200-day moving average of $139.79. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $211.63 billion, a price-to-earnings ratio of -54.01 and a beta of 0.31. Gilead Sciences, Inc. has a 12-month low of $114.02 and a 12-month high of $175.65.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.70%. The business had revenue of $8.30 billion for the quarter, compared to analysts’ expectations of $7.81 billion. During the same period in the previous year, the firm posted $2.47 EPS. The firm’s revenue was up 6.8% compared to the same quarter last year. On average, equities research analysts forecast that Gilead Sciences, Inc. will post -1.03 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be paid a dividend of $0.82 per share. The ex-dividend date is Tuesday, December 15th. This represents a $3.28 annualized dividend and a dividend yield of 1.9%. Gilead Sciences’s payout ratio is currently -103.80%.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q3 results exceeded expectations. Gilead reported adjusted earnings of $2.55 per share versus the $2.19 consensus estimate, while revenue rose 6.8% year over year to $8.30 billion, beating expectations by roughly $500 million. Gilead Sciences Q3 earnings and revenues top estimates
• Positive Sentiment: Management raised its 2026 product-sales outlook to approximately $31.0 billion-$31.3 billion, up from $30.1 billion-$30.4 billion, following strong demand for HIV treatments. Base-business sales excluding Veklury reportedly increased 16%, the company’s strongest growth in more than a decade. Gilead Sciences lifts sales guidance on HIV portfolio strength
• Positive Sentiment: Key growth products performed well. Biktarvy continued to drive HIV sales, while Trodelvy revenue rose 41.7% year over year to $506 million. Livdelzi also contributed to growth, aided by a pan-Canadian public reimbursement agreement that could broaden patient access. GILD beats Q3 earnings on HIV strength and Trodelvy sales growth
• Positive Sentiment: Analyst sentiment improved materially. Citigroup, Scotiabank, Morgan Stanley, Truist, Wells Fargo, Needham and Cantor Fitzgerald all raised their price targets, with several maintaining buy or overweight-equivalent ratings. Targets generally range from $175 to $200. Analysts increase forecasts after upbeat Q3 results
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, equivalent to an annualized $3.28 payout and a stated yield of about 1.9%.
• Negative Sentiment: Longer-term pricing and concentration risks remain. Medicare pricing is expected to reduce Biktarvy’s price by approximately 38% beginning in 2028, potentially cutting annual revenue by about $1.5 billion. Analysts also note that oncology and immunology growth remains less developed, while some coverage characterizes the valuation as demanding after the rally. Gilead hikes 2026 sales outlook and discusses Biktarvy pricing

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.